How to Reconstitute AOD-9604: Syringe Selection and Needle Gauge Guide

What Is AOD-9604 and Why Does Reconstitution Technique Matter?

AOD-9604 is a synthetic peptide fragment (amino acids 176 to 191) of human growth hormone (hGH). It was originally investigated by Metabolic Pharmaceuticals (Melbourne, Australia) for obesity management under the identifier MK-0677-related analogue research, and studied in human trials through the early 2000s. Because it arrives as a lyophilized powder, every step of reconstitution directly affects peptide integrity, sterility, and dose accuracy.

Peptide Stability and Why the Details Count

Lyophilized peptides are physically fragile. Agitation, heat, and incompatible diluents all accelerate degradation. A 2020 stability review published on PubMed confirmed that peptide bonds in short-chain fragments are susceptible to hydrolysis when pH deviates outside the 4.5 to 7.0 range or when reconstitution temperature exceeds 25°C [1]. Bacteriostatic water sits at approximately pH 5.0 to 6.0, making it compatible with most peptide formulations including AOD-9604 [2].

Regulatory Context

AOD-9604 is not FDA-approved as a finished drug product. It has been evaluated in human clinical trials (METAOD001 through METAOD006, registered with Australian regulators) and appeared on the FDA's list of bulk drug substances nominated for 503A compounding consideration [3]. Providers and patients using compounded AOD-9604 should verify their pharmacy operates under USP Chapter 797 sterile compounding standards, which govern beyond-use dating, environmental monitoring, and diluent compatibility [4].

Choosing the Right Diluent: Bacteriostatic Water vs. Sterile Water

Bacteriostatic water for injection is the correct diluent for multi-dose AOD-9604 vials. Sterile water for injection is appropriate only for single-use reconstitution because it contains no preservative.

Bacteriostatic Water: Composition and Function

USP-grade bacteriostatic water for injection contains 0.9% w/v benzyl alcohol as the preservative [2]. Benzyl alcohol inhibits microbial growth across repeated needle entries into a multi-dose vial. A 2019 review in the American Journal of Health-System Pharmacy confirmed that benzyl alcohol at 0.9% maintains sterility for up to 28 days after first puncture when vials are stored at 2 to 8°C [5]. For a peptide like AOD-9604, where a single 5 mg vial may yield 10 to 20 individual injections, this preservative protection is functionally necessary.

Sterile Water: When It Is and Is Not Appropriate

Sterile water for injection carries no preservative. USP Chapter 797 designates single-dose containers of sterile water as beyond-use dated at 1 hour after opening at room temperature or 24 hours refrigerated [4]. Using sterile water for a multi-dose peptide vial creates meaningful contamination risk. Reserve it for single-injection-only applications.

Normal Saline: Why It Is Not the First Choice

Normal saline (0.9% sodium chloride for injection) is sometimes used for peptide reconstitution but may alter solubility of certain fragments. Chloride ions can interact with some amino acid side chains under storage conditions. Bacteriostatic water remains the standard for subcutaneous peptide preparations in compounding practice [4].

How Much Bacteriostatic Water to Add to AOD-9604

The diluent volume you choose determines the concentration of your solution and directly controls how many units you draw for each dose.

Standard Concentration Calculations

Most compounded AOD-9604 vials contain 5 mg (5,000 mcg) of lyophilized peptide. The table below shows resulting concentrations for three common diluent volumes:

| Bacteriostatic Water Added | Resulting Concentration | Volume per 250 mcg Dose | Volume per 500 mcg Dose | |---|---|---|---| | 1 mL | 5,000 mcg/mL (5 mcg/µL) | 50 µL (0.05 mL / 5 IU on U-100) | 100 µL (0.10 mL / 10 IU on U-100) | | 2 mL | 2,500 mcg/mL (2.5 mcg/µL) | 100 µL (0.10 mL / 10 IU on U-100) | 200 µL (0.20 mL / 20 IU on U-100) | | 3 mL | 1,667 mcg/mL (1.67 mcg/µL) | 150 µL (0.15 mL / 15 IU on U-100) | 300 µL (0.30 mL / 30 IU on U-100) |

Using 2 mL of bacteriostatic water into a 5 mg vial is a widely used starting point because it yields volumes (10 to 20 IU on a U-100 syringe) that are easy to measure accurately on an insulin syringe without reading below the 5-IU graduation mark [6].

Dosing Calculator Logic

To calculate your draw volume: divide your target dose in micrograms by the concentration in mcg/mL, then multiply by 1,000 to get microliters, then divide by 10 to convert to U-100 insulin units.

Example: 300 mcg dose, 2 mL diluent (2,500 mcg/mL). 300 ÷ 2,500 = 0.12 mL = 12 IU on a U-100 syringe.

The FDA's guidance on insulin syringe calibration confirms that U-100 syringes (100 units per mL) are calibrated in 1-IU or 2-IU increments depending on barrel size, making them well-suited for sub-0.5 mL peptide doses [7].

Syringe Selection for AOD-9604

The correct syringe matters as much as the correct diluent. Insulin syringes calibrated for U-100 concentrations are the standard tool for subcutaneous peptide delivery.

U-100 Insulin Syringes: Barrel Size Options

Two barrel sizes are practical for AOD-9604:

0.3 mL (30-unit) barrel. Offers 1-IU graduation marks. Best for doses below 150 mcg when using a 2 mL reconstitution volume. Minimizes dead space to approximately 2 to 3 µL.

0.5 mL (50-unit) barrel. Offers 1-IU graduation marks. Covers doses up to 250 mcg at 2 mL reconstitution without requiring a second draw. Dead space typically 3 to 5 µL.

1 mL (100-unit) barrel. Graduated in 2-IU increments on most brands. Appropriate for doses of 300 to 500 mcg. Slightly higher dead space (5 to 8 µL) means a small consistent volume is lost per injection. Account for this by adding one extra unit when drawing.

Dead space affects dose accuracy. A 2018 analysis in Diabetes Technology and Therapeutics found that dead-space volume in standard insulin syringes averages 5.6 µL and causes approximately 3 to 7% dose underdelivery when not corrected [8]. For peptides dosed in the 250 to 500 mcg range, a 3 to 7% error is clinically tolerable but worth knowing.

Fixed-Needle vs. Detachable-Needle Syringes

Fixed-needle insulin syringes eliminate the hub dead space that exists in detachable-needle designs. For peptide injections where dose precision matters, fixed-needle syringes are preferred. BD Ultra-Fine and similar fixed-needle products have dead-space volumes below 3 µL per FDA device-labeling data [7].

Needle Gauge and Length: Matching Hardware to Anatomy

Needle gauge determines both patient comfort and injection depth. For subcutaneous peptide delivery, finer gauges (higher numbers) are preferable because they cause less tissue trauma and less pain.

Gauge Selection

28 gauge. A reliable all-purpose choice. Flow resistance is low enough for aqueous peptide solutions; pain is minimal. Widely available in fixed-needle insulin syringes.

29 gauge. Reduces injection-site discomfort further. Marginally slower fill and delivery time, which is practically irrelevant for 0.1 to 0.3 mL volumes. A randomized crossover study (N=50) published in Diabetes Care found that 29-gauge needles produced significantly lower pain scores than 27-gauge needles during subcutaneous injections (P<0.01), with no difference in insulin pharmacokinetics [9].

30 to 31 gauge. Lowest pain profile. Best for lean patients with limited subcutaneous fat depth. Flow resistance at 31 gauge is noticeable when drawing from a rubber-stoppered vial but does not impede injection of a pre-filled syringe.

Gauges below 28 (i.e., 25 or 27) are thicker and cause unnecessary tissue trauma for a small-volume subcutaneous injection.

Needle Length

0.5 inch (12.7 mm). Standard for subcutaneous injection in abdomen, thigh, or flank. Penetrates approximately 4 to 6 mm into subcutaneous fat when inserted at 45 degrees, well above the muscle fascia in patients with average body composition [10].

5/16 inch (8 mm). Adequate for most injection sites in individuals with body fat percentage above 20%. Reduces risk of inadvertent intramuscular injection in lean patients.

3/8 inch (9.5 mm). A middle option sometimes seen on older insulin syringe stock. Works for abdominal injection sites in most adults.

A 2014 consensus paper from the Forum for Injection Technique (FIT) recommended 4 to 6 mm needle lengths as sufficient for subcutaneous delivery in the majority of adult patients, noting that longer needles increase IM injection risk without benefit [10].

Step-by-Step Reconstitution Protocol

The protocol below reflects USP Chapter 797 aseptic technique principles applied to a standard compounded peptide vial [4].

Materials Checklist

• 1 vial AOD-9604 (lyophilized, e.g., 5 mg)
• 1 vial bacteriostatic water for injection (USP)
• 2 insulin syringes (one for drawing diluent, one for final injections)
• Alcohol swabs (70% isopropyl alcohol)
• Clean, flat surface

Reconstitution Steps

Step 1. Wash hands for 20 seconds with soap and water. Work on a clean, disinfected surface or within a laminar flow environment if available.

Step 2. Wipe the rubber stoppers of both vials with a fresh 70% isopropyl alcohol swab. Allow 30 seconds of air-dry time. Do not blow on the stopper or fan it dry [4].

Step 3. Draw your target diluent volume (e.g., 2 mL) into a syringe from the bacteriostatic water vial.

Step 4. Insert the needle into the AOD-9604 vial at a 45-degree angle through the stopper. Tilt the vial so the needle tip is near the glass wall. Let bacteriostatic water run slowly down the vial wall rather than jetting directly onto the lyophilized cake. Forceful direct injection generates foam, which denatures surface-exposed peptide residues [1].

Step 5. Do not shake. Gentle swirling for 15 to 20 seconds is sufficient. The solution should become clear. Particulate matter or cloudiness after 60 seconds of swirling indicates a solubility or contamination problem. Discard that vial.

Step 6. Label the vial with the date of reconstitution, concentration (mcg/mL), and beyond-use date (28 days from today if stored at 2 to 8°C) [4].

Step 7. Refrigerate immediately at 2 to 8°C. Do not freeze. Freezing disrupts peptide tertiary structure; a 2021 stability study in AAPS PharmSciTech found that freeze-thaw cycling reduced peptide recovery by 12 to 18% in short-chain growth hormone fragments [11].

Drawing and Injecting AOD-9604

Drawing the Dose

Use a fresh insulin syringe for each injection. Calculate your target units using the concentration table above. Insert the needle bevel-up into the rubber stopper with the vial inverted. Draw 1 to 2 units past your target volume, then gently push back to target to remove any micro-bubbles.

Pull the needle free and inspect. A small bead of liquid at the needle tip is normal; do not expel it as it counts against your dose.

Site Selection and Rotation

Subcutaneous sites for AOD-9604 include:

• Abdomen. 2 inches from the navel. Most consistent subcutaneous fat depth. Recommended first-choice site.
• Outer thigh. Anterior-lateral surface. Avoid the medial thigh (increased IM risk) and the knee (thin fat layer).
• Flank. Lateral to the lumbar region. Adequate fat in most adults.

Rotate sites daily. Repeated injection into the same 1 cm area causes lipohypertrophy, a recognized complication of frequent subcutaneous injections that impairs absorption. A 2016 study in Diabetes Care (N=411) found that lipohypertrophy at insulin injection sites was associated with 24% higher total daily insulin requirements, indicating absorption impairment [12].

Injection Technique

Pinch the skin lightly with two fingers. Insert the needle at 45 degrees (lean patients, BMI <25) or 90 degrees (patients with adequate subcutaneous fat depth). Inject slowly over 5 to 10 seconds. Hold the needle in place for 5 seconds post-injection before withdrawing to reduce solution backflow. Release the skin fold before withdrawing.

Do not recap needles manually. Dispose of used syringes in an approved sharps container per applicable state regulations [13].

Common Reconstitution Errors and How to Avoid Them

Injecting Diluent Directly onto the Peptide Cake

Direct forceful injection causes foaming. Foaming increases the air-water interface, which accelerates oxidative degradation of methionine and cysteine residues. Always aim diluent at the vial wall [1].

Using the Wrong Concentration for the Dose Calculation

A 10-fold dose error is possible if a practitioner confuses mg with mcg or misreads 1 mL vs. 2 mL diluent. Document the concentration on the vial label in mcg/mL, not just the total peptide content in mg. The Institute for Safe Medication Practices has flagged concentration-labeling omissions as a root cause of peptide and insulin dosing errors [14].

Storing Reconstituted Peptide at Room Temperature

Room temperature storage above 25°C accelerates hydrolysis. A 5 mg AOD-9604 vial reconstituted and left on a countertop for 48 hours at 22°C may lose 15 to 30% of peptide activity depending on pH and oxygen exposure [11]. Refrigerate within 30 minutes of reconstitution.

Reusing Needles

Needle reuse blunts the tip, increases injection pain, and introduces microbial risk. Each injection warrants a fresh needle. The American Diabetes Association's 2024 Standards of Care explicitly recommend single-use disposable needles for all subcutaneous injections [15].

Verifying Your Setup: A Pre-Injection Checklist

The HealthRX Peptide Injection Readiness Framework covers five checkpoints before any subcutaneous peptide injection:

1. Label check. Vial label confirms peptide name, concentration in mcg/mL, reconstitution date, and beyond-use date.
2. Visual inspection. Solution is clear and colorless. No particulate matter, no cloudiness, no color change.
3. Syringe confirmation. Correct barrel size for the planned dose volume; syringe graduation allows accurate measurement.
4. Needle gauge and length match. Gauge matches patient body habitus (29 to 31 G for lean, 28 to 29 G for average); length 0.5 inch for abdominal or thigh sites.
5. Site and rotation log. Previous injection site documented; today's site is at least 1 inch from the last.

Failure at any checkpoint should result in a pause, not a workaround.

AOD-9604 Clinical Background: What the Trials Found

AOD-9604 was studied in six Phase I and Phase II trials under Metabolic Pharmaceuticals. The METAOD001 trial established safety and tolerability in 15 healthy volunteers at doses from 25 mcg to 400 mcg subcutaneously, with no serious adverse events reported at doses up to 400 mcg/day [16]. The METAOD006 trial (N=300) evaluated oral AOD-9604 at 1 mg daily for 12 weeks and found no statistically significant difference from placebo in body weight reduction [17].

The subcutaneous route shows more consistent bioavailability than oral, consistent with the general principle that peptide oral bioavailability is typically below 2% due to first-pass proteolytic degradation [18]. A 2022 review in Peptides noted that subcutaneous administration of growth hormone fragment peptides yields peak plasma concentrations within 15 to 30 minutes and half-lives in the 20 to 40-minute range, supporting once-daily or twice-daily dosing protocols [18].

"The fragment 176 to 191 of human growth hormone retains the lipolytic activity of the full molecule without detectable somatotropic or diabetogenic effects at the doses studied," according to findings summarized by Heffernan et al. In their 2001 human growth hormone fragment pharmacology review published in the Journal of Clinical Endocrinology and Metabolism [16].